Evaluation of the effect of vincamine teprosilate on behavioural performances of patients affected with chronic cerebrovascular disease.
With a view to determining the efficacy of Teproside versus placebo in patients affected with cerebrovascular disease, 30 subjects, selected at the Montescano Medical Rehabilitation Centre, were randomly divided into two groups of 15 subjects each. After a two-week wash-out period, the first group was treated with placebo and the second with vincamine teprosilate (Teproside) at 120 mg daily, both for a period of 90 days. The assessment of each patient took place in two stages, one at the beginning and one at the end of treatment. It was performed according to both clinical criteria (including an interview with the patient and his family) and neuro-psychological criteria (memory tests, perceptive-spatial and logical functions tests). The data obtained showed a significant improvement of the behavioural performance, the mnemonic ability and the perceptive-motor activity in the Teproside group treated.
D000368:Aged; D001519:Behavior / Q000187:drug effects*; D002561:Cerebrovascular Disorders / Q000188:drug therapy* / Q000523:psychology; D002908:Chronic Disease; D005260:Female; D006801:Humans; D008297:Male; D008568:Memory / Q000187:drug effects; D008875:Middle Aged; D011597:Psychomotor Performance; D012306:Risk; D013037:Spatial Behavior / Q000187:drug effects; D013060:Speech / Q000187:drug effects; D014748:Vinca Alkaloids / Q000627:therapeutic use*; D014749:Vincamine / Q000031:analogs & derivatives / Q000627:therapeutic use*
D014748:Vinca Alkaloids; C038060:vincamine teproside; D014749:Vincamine